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Abstract
Introduction Rats with adjuvant-induced arthritis (AIA)
were necropsied on 14 occasions during preclinical, acute
clinical and chronic clinical stages of AIA progression to
characterize local (joint protein extracts) and systemic
(serum) levels of mediators regulating inflammation and
bone erosion in conjunction with lymphoid tissue-specific
leukocyte kinetics.
Results Systemic increases in alpha1 acid glycoprotein,
tumor necrosis factor-α (TNFα), interleukin (IL)-17, trans-
forming growth factor beta (TGFβ), and chemokine (C–C
motif) ligand 2 (CCL2) together with local IL-1α/β and
TGFβ enrichment and local lymphoid hyperplasia preceded
the onset of clinical disease and joint damage. Systemic
upregulation of TNFα, IL-6, IL-17, TGFβ, IL-18, CCL2,
receptor activator of nuclear factor-κβ ligand (RANKL),
and prostaglandin E2 during acute and/or chronic AIA
coincided with systemic leukocytosis and CD4+ T cell
increase in blood and spleen. In contrast, progression of
joint erosions during clinical AIAwas associated with intra-
articular increases in IL-1α/β, IL-6, RANKL, IL-17,
TGFβ, CCL2, and KC/GRO and also a dramatic decline
in osteoprotegerin.
Conclusion These data indicate that systemic and local
events in inflammatory arthritis are discrete processes,
driven by multiple cellular and humoral mediators with
distinct kinetic profiles.
Keywords Rat adjuvant-induced arthritis . cytokines .
biomarkers . inflammation . bone resorption
Introduction
Rheumatoid arthritis (RA) is an immune-mediated disease
that targets the synovial membrane, articular cartilage, and
bone. The pathogenesis of RA is autoimmunity that drives
chronic soft tissue inflammation and eventually joint
destruction. Production of rheumatoid factors (antibodies
specific for IgG) and/or antibodies directed to cyclic
citrullinated peptides often precedes the clinically detect-
able onset of human RA [1]. Immune-mediated joint
damage is instigated and perpetuated by the release of
many pro-inflammatory cytokines [2, 3]. However, it is still
not clear (1) how cytokine networks are organized within
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systemic and/or local compartments and (2) which cyto-
kines might be the best targets for clinical intervention at
different stages of arthritis progression.
The foremost contributors in patients with rheumatoid
arthritis and related spondyloarthropathies are interleukin-1
(IL-1; chiefly the inducible β form) and tumor necrosis
factor-α (TNFα) [4–7]. Their central importance is dem-
onstrated by the ability of anti-IL-1 or anti-TNF-α biologics
to reduce clinical and structural measures of disease in
arthritic patients [8, 9] and animals with induced arthritis
[10–15]. For this reason, cytokine inhibitors that block the
action of IL-1 or TNF-α are widely used to treat
rheumatoid arthritis and other immune-mediated skeletal
diseases [16–18].
IL-1 and TNFα act synergistically [11, 19] to maintain
inflammation and bone erosions in animal models of joint
inflammation, including adjuvant-induced arthritis (AIA) in
rats [11, 12, 20–22]. However, while inhibition of IL-1,
TNFα, or both yields a significant anti-inflammatory effect
in rats with AIA, residual disease persists [11, 23, 24]. Such
lingering inflammation might be related to submaximal
inhibition of the intended targets or, alternatively, to
potential contributions by other pro-inflammatory cytokines
(e.g., IL-6, IL-12, IL-15, IL-17, IL-18 [25, 26]) and
chemokines (e.g., chemokine (C–C motif) ligand 2
(CCL2) [formerly monocyte chemotactic protein-1 [27]],
CXC chemokine ligand 8 (CXCL8) [formerly IL-8 [28]]).
One or more of these same molecules could represent
additional etiologic factors in the initiation and/or progres-
sion of immune-mediated arthritis. This notion is supported
by the variable responses achieved in human arthritis
patients using existing anticytokine biologics [29–31].
In addition to pro-inflammatory molecules, specific
regulators of bone resorption such as receptor activator of
nuclear factor-κβ ligand (RANKL; a primary mediator of
osteoclast formation, function, and survival) and its soluble
decoy receptor osteoprotegerin (OPG) also play important
roles in immune-mediated joint disease via their ability to
regulate intra-articular osteoclasts [32]. Focal bone erosion
in inflamed joints is a hallmark of immune-mediated
arthritis and has been attributed to excessive RANKL-
mediated osteoclast activity [33–35]. In animal models,
recombinant osteoprotegerin showed anti-erosive effects in
rats with clinical adjuvant- or collagen-induced arthritis [34,
36] and inhibited inflammatory bone loss and erosions in
tumor necrosis factor-transgenic mice [37, 38]. Treatment
of RA patients with denosumab, a fully human monoclonal
antibody that binds and inhibits RANKL, increased bone
mineral density and inhibited RA-related skeletal structural
damage and erosions [39].
To evaluate targets for therapeutic intervention, it is
important to understand the spatial and temporal expression
patterns of the myriad factors that have been implicated in
RA progression. While peripheral blood provides an
expedient source to assess systemic levels of these factors,
joint tissue can also provide important information on local
changes [40–42]. Data comparing local versus systemic
levels of markers and mediators of RA progression are rare
in the literature. However, some of the existing reports
describe divergent levels when comparing for local and
systemic compartments [42–44]. These reports highlight the
likelihood that systemic markers and mediators of arthritis
might not fully reflect the underlying local disease progres-
sion. Basing treatment decisions in such a scenario on
systemic cytokine levels would have a negative impact on
the identification of patients who might benefit from early
intervention and on the choice of appropriate therapeutics.
We performed the current work in a standard rat
adjuvant-induced arthritis model to explore the evolution
of the cytokine spectrum over time in both the local (joint
and regional lymph nodes) and systemic (circulation and
distant lymphoid tissues) compartments. We hypothesized
that the AIA would be associated with distinct cytokine
profiles in the systemic circulation versus the local sites of
inflammation (affected paws). We also hypothesized that
pro-inflammatory molecules other than IL-1β and TNFα
would surface as potentially major players (and useful
biomarkers) in launching and sustaining arthritis. Our
present data show that cytokine profiles in immune-
mediated arthritis differ substantially in the local and
systemic settings and indicate that elevated intra-articular
IL-17 may be a significant driver of local joint destruction.
Materials and Methods
These studies were conducted in accordance with federal
animal care guidelines and were preapproved by Amgen’s
Institutional Animal Care and Use Committee.
Experimental Design
Rat AIA is a well-characterized model for assessing
arthritis mechanisms [10, 11, 23, 24, 34, 45, 46]. For this
study, disease was investigated by taking clinical measure-
ments as well as fluid (serum) and tissue (hind paws, femur,
lymphoid organs) samples on 14 occasions: before onset
(−5, −3, or −1 days), at onset (indicated by hind paw
swelling and ambulatory difficulties), and during clinical
arthritis progression (+1, +2, +3, +4, +5, +7, +10, +14, +20,
and +27 days after onset).
Animals
Male Lewis rats (7 to 8 weeks old; Charles River,
Wilmington, MA, USA) were acclimated for 1 week and
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then randomly assigned to treatments (14 AIA groups with
n=8 per time point and 28 nonarthritic controls [two per
time point]). This cohort size was used because interindi-
vidual variability is minimal between untreated rats with
AIA [11]. Animals received tap water and pelleted chow
(#8640, Harlan Teklad, Madison, WI) ad libitum; calcium
and phosphorus were 1.2% and 1.0%, respectively.
Induction of Arthritis
AIA was induced as described [11] by a single intradermal
injection at the tail base of heat-killed Mycobacterium
tuberculosis H37Ra (0.5 mg; Difco Laboratories, Detroit,
MI, USA) suspended in 0.05 ml paraffin oil (Crescent
Chemical Co., Hauppauge, NY, USA). The day of disease
induction was designated as study day 0.
Assessment of Arthritis
Clinical Evaluation Total body weights were gathered to
assess general health. Joint swelling was examined by
measuring average hind paw volume via water plethysmog-
raphy [11] or diameter via precision calipers [42].
Hematologic Assessment At necropsy, blood was collected
by intracardiac puncture from rats anesthetized with CO2. A
complete blood count was acquired from ethylenediamine-
tetraacetic acid-treated whole blood using an Advia 120
analyzer (Bayer Corporation, Tarrytown, NY, USA). Flow
cytometry (FACSCalibur; BD Biosciences, San Jose, CA,
USA) to quantify leukocyte subpopulations was performed
on whole blood and selected local (popliteal and inguinal
lymph nodes) and systemic (mesenteric lymph node and
spleen) lymphoid organs (dissociated in PBS) using
antibody reagents (BD PharMingen, San Diego, CA,
USA) directed against cell surface markers specific for B
(CD45RA) and T (CD3, CD4, CD8) lymphocytes, antigen-
presenting cells (CD11b/c), granulocytes (HIS48), and
macrophages (HIS36).
Protein Extraction from Joints One tibiotarsal region from
one hind paw was flash-frozen, pulverized, and extracted
using a 50-mM Tris buffer, pH 7.4, containing 0.1 M NaCl
and 0.1% Triton X-100. Protein concentration in individual
extracts was evaluated using a standard BCA Protein Assay
(Pierce Co., Rockford, IL, USA).
Biochemical Assays for Serum and Joint Extracts Separate
aliquots of serum or paw protein extracts were used to
quantify levels of various analytes. The major rat acute phase
protein alpha1 acid glycoprotein (α1AGP) was measured by a
precipitin ring assay (Ecos Institute, Furukawa, Miyagi,
Japan). Multiple cytokines (IL-1α/β, TNFα, transforming
growth factor beta (TGFβ), IL-2, IL-4, IL-10, IL-12, I IL-17,
IL-18, IL-6, CCL2, KC/GRO, granulocyte monocyte colony-
stimulating factor (GM-CSF), interferon (IFN)γ, RANKL)
were assessed using multiplex rat-specific Luminex kits
(Linco Research, St. Charles, MO, USA), or single-plex
mouse OPG-specific Luminex kits (Linco Research, St.
Charles, MO, USA); the mouse OPG kit was 95% to 98%
cross-reactive with rat OPG based on a comparison of
standard curves for recombinant mouse OPG (internal kit
standard) vs. recombinant rat OPG (Amgen Inc., Thousand
Oaks, CA, USA). Prostaglandin E2 (PGE2) was evaluated
using an enzyme immunoassay kit (Cayman Chemical, Ann
Arbor, MI, USA). Total immunoglobulins were determined
by enzyme-linked immunosorbent assay (Bethyl Laborato-
ries, Montgomery, TX, USA). Concentrations of humoral
immune modulators in paw protein extracts were evaluated
as described above and normalized to the total protein
concentration. Assays were performed according to the
manufacturers’ instructions.
Histopathology The other hind paw was removed, fixed by
immersion in zinc formalin, decalcified in eight serial
changes of a 1:4 mixture of 8 N formic acid and 1 N
sodium formate for approximately a week, trimmed, and
processed into paraffin. The extent of local disease was
evaluated in the paw at all time points using standard
criteria and a blinded analytical paradigm (Table I; [11]).
Analyses were done in sections stained with hematoxylin
and eosin (H&E).
Detection of TNFα Expression in Joint Tissue by In Situ
Hybridization Additional serial 5-μm-thick hind paw sec-
tions of the nonarthritic control and AIA cohorts were
processed using a conventional in situ hybridization (ISH)
protocol to localize TNFα. A 185-bp DNA fragment of the
rat TNFα gene, corresponding to nucleotides 2115–2300
(GenBank #D00475) was cloned into the pGEM-T vector
(Promega Corp., Madison, WI, USA) for use as a template.
An antisense 33P-labeled RNA probe was synthesized with
Sp6 RNA polymerase after linearization with BamHI
restriction enzyme. The TNFα riboprobe produced strong
signal in the positive control tissue (colon from B7RP1
mouse colitis model [47]), indicating that the probe was
sound. Hind paw sections were hybridized with the probe
overnight at 60°C, followed by RNase digestion and a
series of SSC washes with highest stringency of 0.1X SSC
at 55°C for 30 min. Slides were subsequently air-dried and
exposed on a phosphor screen overnight. Screens were
scanned with a Storm 840 PhosphorImager (GE Healthcare,
Piscataway, NJ, USA), but the signal was not quantified.
Finally, the slides were coated with NTB2 emulsion
(Kodak, Rochester, NY) and exposed for 3 weeks in the
dark at approximately 4°C, developed, and then counter-
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stained with H&E. Degree of expression in each slide was
subjectively evaluated under dark field microscopy, and
ISH signal intensity was assessed using a semiquantitative
grading scale: (−)=no signal, (+/−)=equivocal, (+)=weak/
low, (++)=moderate, and (+++)=strong.
Statistical Analysis Results are expressed as mean±stan-
dard error of the mean (SEM). Student’s t test was used for
the clinical data by comparing AIA vs. control rats.
Histopathology data were analyzed using the chi-square




The clinical progression of AIA followed the typical course
described previously [11]. Briefly, clinical onset of AIA in all
animals occurred on study day 9 and was always observed
first in hind paws as soft tissue swelling. Fore paws were not
affected until 7 days after hind paw swelling became evident.
Hind paw diameter peaked by onset +7 days, while paw
volume increased until onset + day 10 (data not shown).
Significant (p<0.05) body weight loss (compared with
healthy control group) developed 2 days after disease onset
and progressed through onset +10 days, after which body
weight stabilized (data not shown).
Anatomic evidence of arthritis paralleled clinical disease.
The earliest evidence of joint involvement was the
existence of minimal leukocyte infiltration in the hind
paw on the day of disease onset (Fig. 1a). Histologic
evidence of inflammation in the paw peaked at 7 and
10 days after onset, and this inflammation then declined
modestly through the end of the study (Fig. 1a, c). Bone
erosions were significantly (p<0.05) increased in paw
sections beginning 2 days after disease onset (Fig. 1b;
published previously in [42]) and peaked at 10 days after
onset (Fig. 1b, c).
Based on these macroscopic and microscopic patterns,
AIA progression was divided into three stages: (1)
preclinical (from day −9 before onset to the day of
clinically visible arthritis onset [designated day 0]), where
evidence of inflammation or bone erosion was lacking; (2)
acute clinical (from day 0 to +10 post-onset), where hind
paw swelling and body weight loss (macroscopic) as well
as inflammation and joint erosion (microscopic) were
steadily progressing; and (3) chronic clinical (day +11
post-onset and beyond), where clinical (paw swelling, body
weight changes) and structural (inflammation and articular
erosions) evidence of joint involvement had reached a
plateau.
Hematologic Changes
Circulating blood cell populations in arthritic animals were
altered at all time points, including those taken before joint
swelling was first detected (Fig. 2a). Prior to disease onset,
mean neutrophil and monocyte numbers were increased,
and these populations remained high throughout the study.
An increase in “large unstained cells” (thought to be
activated lymphocytes [48] or giant granulocytes or mono-
cytes) from 1% to 3% was evident during clinical AIA
(data not shown). Lymphocytes (both B and T cells) were
reduced prior to onset and remained low during progres-
sion. Within the T cell population, the CD4+/CD8+ cell
ratio was significantly shifted towards CD4+ helper T
lymphocytes during acute clinical stage of AIA (i.e.,
between onset and day +5; Fig. 2a). This blood signature,
where all the subsets of myeloid cell linage were increased,
was repeated in the spleen (Fig. 2b). The difference in the
CD4+/CD8+ cell ratio in spleen was elevated between
onset and onset +4 days (i.e., during acute disease) and
remained high through the chronic stage of AIA. The
percent but not absolute numbers of T (25%) and B (27%)
lymphocytes residing in spleen during AIA were signifi-
cantly lower (p<0.05 compared to non-AIA control) than
the similar populations in control rats (35% to 40% for both
lymphocyte subsets in non-AIA control).
Hematological and flow cytometric analyses of lymph
node cell suspensions revealed that resident leukocyte




1 Few inflammatory cells
2 Mild inflammation
3 Moderate inflammation
4 Marked inflammation (generally diffuse)
Erosion
0 Normal
1 Minimal loss of cortical or trabecular bone at a
few sites
2 Mild loss of cortical or trabecular bone at modest number of
sites (generally tarsals)
3 Moderate loss of bone at many sites (usually the trabeculae of
the tarsals, but sometimes the cortex of the distal tibia)
4 Marked loss of bone at many sites (usually as extensive
destruction of trabeculae in the tarsals, but sometimes with
partial loss of cortical bone in the distal tibia)
5 Marked loss of bone at many sites (with fragmenting of tarsal
trabeculae and full thickness penetration of cortical bone in
the distal tibia)
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populations (Fig. 3) in local lymph nodes (inguinal and
popliteal LNs) were already altered during the preclinical
stage of AIA. The mean number of leukocytes residing in
inguinal and popliteal LNs rose from 5×106 and 0.8×106
(basal level in control rats correspondingly) to 39×106
(inguinal LN) and 4.4×106 (popliteal LN) at 5 days before
onset, ultimately peaking at 102×106 (inguinal LN) and
25×106 (popliteal LN) at the peak of acute AIA (onset
+5 days). The cellular composition of draining LNs did not
change greatly as AIA progressed; 90% to 95% of resident
cells in arthritic rats were lymphocytes. Both the absolute
numbers and percent composition of myeloid cells (neu-
trophils and monocytes) in local LNs rose significantly
from 3% (baseline) to 6.7% at the peak of active disease (7
to 10 days after onset). The absolute number of B and T
lymphocytes in local nodes of affected rats was significant-
ly elevated at all the stages of AIA progression. In contrast
to blood and spleen, the CD4+/CD8+ ratio in the T
lymphocyte population in local LNs was not changed
throughout the course of disease compared to nonarthritic
controls (data not shown). The cellularity of distant
(mesenteric) LNs was not altered at any stage of disease
progression (data not shown).
Systemic Immunoglobulin Changes
Serum immunoglobulin levels exhibited significant en-
hancement, with two patterns of expression (Fig. 4).
Circulating IgM levels (an efficient activator of the classical
complement pathway) and total IgG (the predominant
antibody of the secondary immune response) were signif-
icantly elevated (two- to eightfold) for the first 3 days after
onset (acute stage of AIA). IgG1 and IgG2a (principal
elements of Th1- or Th2-type immune responses, respec-
tively [49]) as well as IgG2b followed the same course as
total IgG. However, IgE as well as IgG2c (a comarker
together with IgM for B cell activation in the splenic
marginal zone [50]) were significantly amplified throughout
the disease, starting with a transient spike initially (tenfold
rise for the IgG isoforms, 300-fold for IgE) before partially
regressing.
Systemic and Local Changes in Biochemical Markers
of Inflammation
Concentrations of selected immune modulators, pro-inflam-
matory and anti-inflammatory cytokines, and chemokines
were measured both systemically (in serum; Fig. 5a) and
locally (in hind paw protein extracts; Fig. 5b). Tissue and
serum levels exhibited no correlation for several entities,
including molecules generally considered to be primary
regulators of the pro-inflammatory cascade (e.g., TNFα,
IL-1, IL-17, IL-6).
In rats, α1AGP is the dominant acute phase protein
whereas in human beings, C-reactive protein is more
prominent [51]. Concentrations of serum α1AGP were
significantly increased throughout the study beginning
5 days before disease onset, and the divergence relative to
controls became extreme (5,000-fold increase) beginning





















-5   -3     0   2   4      7     10  14          20            27
Day Relative to Disease Onset






















Control AIA Day +4




Fig. 1 Progression of adjuvant-induced arthritis in hind paws as
indicated by histopathologic scores for inflammation (a) and joint
erosion (b) and representative images (c; magnification=×0.5, stain=
H&E). Mean(±SEM) of arthritic groups (triangles) defined by
brackets were significantly different from values of controls (straight
line). Onset of clinical disease in the hind paw is designated as day 0
on the x-axis. Note: the erosion panel (b) has been reproduced from
[42] with permission of the American Society for Bone and Mineral
Research
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Fig. 2 Changes in leukocyte pop-
ulations circulating in blood (a) or
residing in spleen (b) during AIA
progression. Mean(±SEM) of
arthritic groups encompassed by
the bracket were significantly
different from controls (horizontal
hatched bar represents mean±
SEM of controls)
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3 days after onset (2.54 mg/ml; Fig. 5a). Elevated levels of
α1AGP were also measurable in paw protein extracts (40–
50 μg/mg protein) beginning at onset +3 days.
Serum TNFα concentration was modestly but significant-
ly elevated at 23 pg/ml beginning 5 days before onset and
remained at around this level for most of the study. Serum
TNFα exhibited two peaks, one during acute disease at
4 days after onset (31 pg/ml) and a second at onset +10 days
(27 pg/ml). Surprisingly, in joint extracts, TNFα was
undetectable (i.e., levels below the assay detection limit of
1 pg/ml) throughout the study. This lack was not due to an
assay artifact as recombinant rat TNFα could be measured at
concentrations as low as 5 pg/mg total protein when added to
paw homogenates (data not shown). This cytokine also was
not detected in joints or serum of control rats. By in situ
hybridization, a low diffuse TNFα signal was first seen in
arthritic hind paws during the acute clinical stage of AIA
(beginning at 4 days after onset); TNFα expression was
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Fig. 3 Changes in leukocyte
populations within local lymph
nodes (a inguinal and b popliteal)
during AIA progression. Mean
(±SEM) of arthritic groups
encompassed by the bracket
were significantly different from
controls (horizontal line repre-
sents mean±SEM of controls)
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never detected in control paw samples (Fig. 5c). This pattern
continued essentially unchanged throughout the chronic
clinical stage of AIA, although occasional focal patches of
moderate labeling were evident in marrow spaces adjacent to
eroding bone (Fig. 5c).
Serum IL-17 was significantly higher in AIA rats as
early as 3 days before disease onset (22 to 35 pg/ml in AIA
rats vs. undetectable levels in controls; Fig. 5a). This initial
rise in IL-17 presaged a peak concentration of 100 to
150 pg/ml during the acute phase (from 1 to 7 days after
onset) followed by a gradual decline to a lower steady-state
level of 32 to 56 pg/ml. In arthritic rats, evidence of
increased IL-17 in paw protein extracts was first measurable
at onset +2 days after onset; this time coincided with the
peak serum concentration, though tissue levels were much
lower level (18 pg/mg of total protein). As in serum, IL-17
was not detected (minimal detectable level >1.6 pg/ml) in
paw protein extracts from control animals.
IL-1α was not detected in serum but was significantly
increased in AIA paw extracts (203 pg/mg total protein
vs. undetectable level in controls) 5 days before disease
onset. The tissue concentration of IL-1α declined
substantially by 3 days before onset to 51 pg/mg of
total protein, although this level was still significantly
above tissue IL-1α levels in controls. Incremental but
significant increases in tissue IL-1α (range, 57 to 66 pg/
mg total protein) were also detected at early acute AIA
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Day Relative to Disease Onset
Fig. 4 Circulating immuno-
globulin levels during AIA pro-
gression. Mean(±SEM) of
arthritic groups encompassed by
the bracket were significantly
different from controls (hori-
zontal hatched bar represents
mean±SEM of controls)
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IL-1β in the joint extract first achieved a significant
increase at preclinical AIA (3 days prior to AIA onset),
after which it rose steeply to peak 3 days after onset at
545 pg/mg total protein before rapidly declining to a
lower steady-state level of 90 to 120 pg/mg total protein.
The serum IL-1β concentration was not significantly
increased until onset +14 days, and the peak level
(61 pg/ml) was substantially lower than that measured
in paw tissue.
IL-6 cycled in a manner comparable to IL-1β. Tissue IL-6
rose rapidly beginning at onset to peak 2 days after onset at
5.9 ng/mg total protein (vs. undetectable level in controls)
before rapidly declining to a lower steady-state range of 0.3 to
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Fig. 5 Systemic (a serum) and
local (b hind paw protein ex-
tract) concentrations of pro- and
anti-inflammatory cytokines and
chemokines during AIA pro-
gression. Mean(±SEM) of ar-
thritic groups encompassed by
the bracket were significantly
different from controls (hori-
zontal hatched bar represents
mean±SEM of controls). The
low intra-articular expression of
TNFα was confirmed by in situ
hybridization (c), where signal is
generally lacking near the na-
vicular tarsal bone (the principal
site of AIA [enclosed by solid
square box]) except for small
foci of moderate signal (dotted
circles) in the marrow and peri-
articular soft tissues well after
AIA onset
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day of disease onset, reaching a lower maximal level (216 pg/
ml) at onset +4 days before declining gradually to basal levels.
TGFβ concentrations in serum and paw protein extracts were
significantly increased (p<0.05 compared to nonarthritic
controls) at the preclinical stage of AIA progression and
continued to be significantly higher in blood but not paw
tissue extracts during acute clinical AIA.
IL-18 was found in greater quantities in AIA tissue
(compared with non-AIA control) but persisted for a longer
period in blood. Tissue IL-18 was modestly but signifi-
cantly augmented only from onset +1 to onset +3 days
(range, 4.7 to 6.4 ng/mg total protein), after which levels
fell below those detected in control animals. In contrast,
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bFig. 5 (continued)
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5 days before onset. The peak serum level (101 pg/ml)
occurred at onset +4 days.
Serum CCL2 was transiently but significantly increased 5
and 3 days before disease onset (range, 105 to 120 pg/ml),
and later from onset to onset +14 days. The peak serum level
attained was 157 pg/ml at onset +4 days. Tissue CCL2 rose
rapidly beginning at disease onset to reach a peak level of
301 pg/mg total protein at onset +3 days before undergoing a
swift decrease by onset +10 days.
KC/GRO (a chemoattractant and activating factor for
neutrophils) followed the same pattern as IL-1β and IL-6.
Joint levels increased quickly starting at onset to peak at
1.4 ng/mg total protein by onset +2 days before rapidly
declining to a lower steady-state level (200 pg/mg total
protein). Serum KC/GRO concentrations also began in-
creasing at onset, again achieving a much lower peak level
of 885 pg/ml by 2 days after onset before undergoing a
measured decline to levels around 600 pg/ml.
PGE2 was not detected in tissue protein extracts, but serum
PGE2 concentration was first significantly elevated 3 days
after onset and remained so throughout acute and chronic
stages of AIA progression. While IFNγ was found to be
increased transiently in AIA serum (peaking at 66 pg/ml
between 2 to 5 days after onset), the systemic and local levels
of IL-2, IL-4, IL-10, IL-12, and GM-CSF were not changed
(compared with the control non-AIA animals) at any
examined time point of AIA progression (data not shown).
Systemic and Local Changes in Pro- and Anti-erosive Bone
Markers
Systemic and local expression of pro- and anti-erosive bone
markers were well correlated (Fig. 6). Local levels of
RANKL in paw tissue extracts were markedly increased in
AIA rats. As reported previously [42] and reiterated here
for context, an initial significant rise at 3 days after onset
was followed by sustained elevation (two- to fourfold
higher than nonarthritic animals) for 20 days. Serum
RANKL was significantly greater 2 days after onset and
remained high (up by at least 38%) throughout the study. In
contrast, local OPG levels underwent a significant and
sustained decline beginning 1 day after onset (273 pg/mg in
AIA rats vs. 1,533 pg/mg in control). Interestingly, OPG
levels in serum of arthritic rats were moderately elevated
(1.2- to 1.5-fold) throughout the chronic stage of disease
(onset +7 days and later; p<0.05). The local RANKL to
OPG ratio in AIA rats was significantly enhanced by 33-
fold at 1 day after disease onset relative to that in control
animals. The disparity in the balance of intra-articular
RANKL and OPG climbed rapidly, peaking with a 65-fold
increase over the control ratio 5 days after onset; this
divergence persisted for the remainder of the study. By
comparison, the serum RANKL/OPG ratio in arthritic rats
was much less dramatic with a 2.5-fold increase vs. control
(p<0.05).
Discussion
In recent years, cytokine and chemokine production in
clinical RA has attracted considerable interest since many
such molecules are involved in regulating the immune
system and its inflammatory response [52]. Numerous cell
types in the inflamed synovium of arthritic joints in human
patients or animal models can produce cytokines, including
recruited leukocytes (activated T lymphocytes, macro-
phages, and plasma cells) and resident synovial fibroblasts
and endothelial cells [40, 41]. Recent experimental and
clinical research with anticytokine biologics confirms that
TNFα and IL-1 are dominant mediators of immune-
mediated joint disease in people [4, 8, 9, 19, 53, 54] and
experimental animals [11–15]. However, the variable
efficacy attained in human arthritis patients using existing
IL-1 and TNFα inhibitors coupled with the demonstrated
utility of targeting other pro-inflammatory entities [29, 30]
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disease. Many pro-inflammatory cytokines (IL-6, IL-12, IL-
15, IL-18 [for review, see [26]] and IL-17 [25]) and
chemokines (CCL2 [27] and CXCL8 [28]) as well as the
proresorptive cytokine RANKL [45] have been implicated
as potential arthritis mediators based on their presence
within inflamed joints or because anticytokine biologics
have been shown to reduce disease severity in animal
arthritis models [26, 55, 56].
Accordingly, we devised the current experiment in a
standard rat AIA model of immune-mediated joint disease
to test two hypotheses. First, we predicted that arthritis
would be accompanied by unique local (joint and regional
lymph nodes) and systemic (serum and distant lymphoid
tissues) combinations of cytokine patterns and altered
leukocyte populations characterized by modest to no
overlap in their compositions. Second, we posited that
intra-articular concentrations of one or more other pro-
inflammatory molecules in addition to IL-1 and TNFα
would be so elevated during preclinical and/or early clinical
stages of disease that these entities could also be assigned
roles as major players in the induction and maintenance of
AIA. An anticipated corollary outcome of these two
hypotheses was that serum biomarker signatures of joint
disease might not truly reflect the most important mediators
in joint tissues. Our results confirm that these two
hypotheses as well as the corollary conclusions are
accurate.
In accord with our first hypothesis, the biochemical and
cellular compositions in the local compartments and
systemically were substantially different. This conclusion
is supported by two lines of evidence. First and foremost,
the two major pro-inflammatory cytokines were confined to
separate compartments; IL-1 was restricted entirely (α
variant) or mostly (β form) to arthritic joints, while
detectable protein level of TNFα was limited to serum
(Fig. 5). This compartmentalization of IL-1 locally and
TNF systemically is consistent with prior experiments
demonstrating that joint destruction and osteoclast forma-
tion are more predominant with local application of IL-1
[57]. Instillation of IL-1 into the joint but not TNFα
augments osteoclast numbers locally [20], and anti-IL-1 but
not anti-TNF biologic therapy has been shown to inhibit
angiogenesis in hind paws of rats with AIA [10]. Systemic
TNFα augments the process by releasing osteogenic
precursors from the bone marrow and by ‘priming’ them
to respond to RANKL [58, 59]. This interpretation is
Local (hind paw protein extract) Systemic (serum)
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concentrations of bone turnover
markers during AIA progres-
sion. Mean(±SEM) of arthritic
groups encompassed by the
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SEM of controls). The RANKL
panels have been reproduced
from [42] with permission of the
American Society for Bone and
Mineral Research
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further supported as a general principle for pro-arthritic
signaling molecules by our prior demonstration that
different systemic and local concentrations of RANKL
(a TNF superfamily member that is an essential mediator of
bone erosions) were strongly correlated with the induction
of divergent degrees of systemic and local osteopenia in
rats with AIA starting as early as the day of disease onset
[24, 42]. Secondly, the nature of the inflammatory changes
differed in regional lymph nodes (inguinal, popliteal)
relative to more distant lymphoid tissues (mesenteric lymph
nodes, spleen). Regional lymph nodes as well as the splenic
white pulp exhibited reactive hyperplasia, but the regional
nodes responded earlier and more robustly (Figs. 2b and 3).
This anatomic distinction was reflected in absolute cell
counts, as local nodes contained significantly more neu-
trophils, monocytes, and lymphocytes (mainly B cells;
Fig. 3), while more distant nodes did not (data not shown).
Interestingly, the significant influx of B and T cells into
local lymph nodes coincided with the peak of immuno-
globulin levels in AIA serum (Fig. 4) but was the reverse of
the situation in spleen, where these two populations of
lymphocytes were reduced relative to those in control rats
(Fig. 2b). These unique biochemical and cellular signatures
first began developing well before AIA onset (Figs. 2, 3,
and 5). Furthermore, increases in concentrations of several
pro-inflammatory mediators were profound in serum and/or
paw protein extracts (Table II): acute phase protein α1AGP
(20-fold greater), CCL2 (100-fold more), IL-18 (50-fold
higher), IL-17 (from undetectable levels in control animals
to 100–150 pg/ml in AIA rats), TGFβ (2.4 times higher),
and TNFα (up by 10–30%). The fact that these molecules
were elevated before the onset of clinical AIA positions
them as potentially critical mediators and/or markers of
disease induction, a supposition made stronger by our
demonstration that this pro-inflammatory signature coin-
cided with dramatically increased levels of IL-1 and TGFβ
in paw protein extracts (Table II).
Our second hypothesis, that elevated cytokine levels
before onset and/or during early clinical disease would
identify a given molecule as a participant in the induction
and maintenance of joint disease, also appears to be true for
several of the entities measured in the current experiment.
The most intriguing such finding was high serum (system-
ic) concentrations of IL-17 before AIA onset. This
discovery strongly bolsters the proposed role for IL-17, a
pro-inflammatory cytokine produced by CD4+ T cells, as a
potent inducer and enhancer of inflammation and damage
in the RA joint [60, 61]. Several cytokines capable of
inducing the differentiation of Th1 T cells into IL-17-
producing T cells (Th17)—TGFβ, IL-1, TNFα, IL-18—
were all elevated systemically or/and locally before AIA
onset in the present experiment. The site where Th1 and/or
Th17 cells were induced to differentiate and expand into
pathogenic effector cells in rheumatoid arthritis is not
known yet, but the fact that at the preclinical stage of AIA
the CD4+/CD8+ T cell ratio is shifted toward the CD4+
subset systemically (blood and spleen) but not locally
(within draining inguinal and popliteal LNs) permits the
speculation that Th17 T cells are transformed into patho-
genic effectors systemically and then circulate widely,
including regular forays into the sites of local inflammation
(i.e., joints). Furthermore, a synergistic effect among IL-17,
IL-1, TGFβ, and TNFα could drive differentiation,
maturation, activation, and cytokine release by neutrophils,
monocytes, and synovial fibroblasts [60, 62, 63], thereby
leading eventually to the visible onset of clinical arthritis in
RA patients and experimental animals.
The second molecule which our current experiment
identified as a potential major player in the induction of
AIA was CCL2, which was highly elevated in serum of
AIA rats during the preclinical stage of disease progression.
CCL2 is chemotactic for monocytes and T cells, and it has
been detected at high levels in synovial fibroblasts from RA
patients [64], especially in response to IL-1 and TNFα.
Presumably, the main function of CCL2 during the
preclinical stage of AIA will be to recruit circulating
monocytes to become tissue macrophages within the joint.
This premise is supported by the increased absolute number
of monocytes within the circulation (Fig 2a) as well as local
Table II Comparison of systemic and local changes in biomarkers
relative to the progression of rat AIA
Marker
AIA vs. Control 






Acute Chronic Acute Chronic
α1AGP =
TNFα =
IL-1α = = = =
IL-1β = =
IL-17 =









TRACP-5B [42] = = = =
= No changes, one triangle 1.3- to >2-fold change, two triangles 2- to
>3-fold change, three triangles ≥3-fold change, red detected by
protein assay, yellow detected by in situ hybridization
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lymph nodes (Fig. 3) and the spleen (Fig. 2b) long before
AIA onset.
Our demonstration that (1) levels of many mediators
other than IL-1 and TNFα [10, 12, 57, 65] undergo
pronounced alterations over time before and during AIA
and that (2) the chemokine/cytokine availability in local
and systemic compartments is divergent (Table II) strongly
implies that cytokine action is partitioned in both time and
space. For example, IL-1α was found only in joints, while
TNFα and PGE2 were elevated only in serum. Some
molecules were accentuated chiefly during the early phases
of AIA evolution (e.g., CCL2, IL-1α, IL-1β, IL-6, and KC/
GRO in joints; IL-17, CCL-2, IFN-γ, IL-6, and KC/GRO in
serum), others were found most prominently during the
later periods (e.g., IL-1β in serum), and still others
exhibited either intermittent spikes or relatively consistent
elevations that compassed the entire study (e.g., IL-18 and
TNFα in serum). Presumably, arthritis is driven mainly by
soaring tissue levels of pro-inflammatory mediators, while
systemic inflammation is impelled by amplified circulating
levels. This supposition, if true, implicates IL-1 (both
forms), IL-6, IL-17, CCL2, and possibly KC/GRO as the
key local signals for inciting joint lesions in AIA. Previous
work implicating IL-18 [26] and TNFα [54] as possible
mediators in rheumatoid arthritis suggests that these two
molecules should receive further study as potential players
in AIA, even though they were not detected in afflicted
joints in this study.
This argument regarding pro-inflammatory mediators is
readily extrapolated to molecules that specifically regulate
bone turnover, such as RANKL (a marker and mediator of
enhanced bone resorption capacity) and OPG (which
prevents bone resorption and preserves bone). Analysis of
synovial tissue from patients with active RA demonstrated
a lack of OPG expression in conjunction with significant
RANKL expression [66, 67]. Our current time-course data
(Fig. 6) convincingly showed that the onset of a major
imbalance in the intra-articular RANKL to OPG ratio—the
consequence of exacerbated RANKL production in con-
junction with a precipitous OPG decline—coincided with
the earliest evidence of bone destruction in arthritic joints.
Concentrations of OPG protein in rats had not been
described in the literature previous to this study due to the
lack of available rat OPG assays. The novel finding of
suppressed OPG levels in arthritic paws was facilitated by
our identification of a commercially available luminex-
based singleplex mouse OPG assay that strongly cross-
reacted with recombinant rat OPG standards. Prior to this
discovery, conclusions regarding the possible impact of
elevated total RANKL levels in rats were tempered by the
lack of corresponding information on OPG levels. The
RANKL to OPG ratio is considered an important determi-
nant of bone resorption in arthritis [68]. The new ability to
quantify OPG and RANKL in rats is an important advance
due to the widespread use of rats as models for investigat-
ing human bone disease. As a first application, we
determined (Table II) that the local reduction in intra-
articular OPG protein levels and the associated increase in
the RANKL to OPG ratio coincided with significant local
increases in intra-articular osteoclast numbers and levels of
the osteoclast marker TRACP-5b [42]. Given the extreme
proresorptive state associated with the local increase in
RANKL to OPG ratio, we posit that RANKL is the primary
driver of bone erosion in AIA. Other molecules such as IL-
1β, IL-17, and TNFα might promote further bone
destruction by recruiting preosteoclasts and promoting
osteoclast differentiation [69–71] and/or by modulating
RANKL and OPG levels [72–74]. The dominance of
RANKL in mediating bone erosions is further supported
by the ability of OPG to cause greater suppression of bone
erosions compared to inhibitors of TNFα or IL-1, even
when OPG treatment is undertaken in the presence of
severe ongoing joint inflammation [11, 23].
Our current data showing that measurement of serum
RANKL appears to offer a good means of monitoring the
progression of bone erosion once disease has become
clinically established. Additional work with rheumatoid
arthritis patients will be needed to define what other
systemic markers of bone resorption would be suitable
markers for following early disease [75].
Data from this study suggest that the measurement of
serum biomarkers may not adequately predict whether or
not a patient will respond to a given anticytokine biologic.
While sampling of synovial tissue or fluid from arthritic
patients could help to tailor appropriate therapies, this is
probably an impractical routine. Our results may provide
scientific justification for the current clinical practice of
employing frontline cytokine inhibitors in rotation until an
optimal disease-modifying response is obtained. The
rationale for this empirical approach is that intra-articular
increases in certain cytokines might not be evident in the
peripheral circulation, where diagnostic samples are typi-
cally collected. These results provide a framework for the
evaluation and validation of new and existing therapeutic
targets by identifying the spatial and temporal expression of
numerous cytokines and other factors thought to be
involved in the progression of inflammatory arthritis.
Conclusions
These data have provided substantial new insights regard-
ing the molecular pathogenesis that initiates and perpetuates
AIA in rats. The design of our study has afforded us new
understanding of the main phases of AIA—premonitory
(preclinical), initiation (acute [day of onset to onset +
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10 days]), and maintenance (chronic [onset +11 days and
beyond])—as well as an initial view of some molecular
events that appear to drive each stage. Our AIA experiment
has revealed that local damage in affected joints is initiated
and sustained principally by the pro-inflammatory mole-
cules IL-1 (both α and β forms), IL-6, TGFβ, IL-17, and
CCL2 along with the pro-erosive entity RANKL (coupled
with a marked decline in the bone-protective RANKL
inhibitor, OPG), while systemic manifestations of inflam-
mation are driven by TNFα, IL-17, IL-18, TGFβ, CCL2,
PGE2, and acute phase proteins. The evaluation of serum
RANKL should be considered as an appropriate biomarker
of ongoing but not imminent bone erosion. We hope that
improved understanding of arthritis mechanisms afforded
by these AIA data will enhance our collective abilities to
define new targets and diagnostic tests that may be
translated into useful new avenues for treating immune-
mediated joint diseases in human patients.
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